Steven E. Fleck
Directeur Financier/CFO chez CDG Therapeutics, Inc.
Profil
Steven E.
Fleck has been Chief Financial Officer of CDG Therapeutics, Inc. since April, 2006.
Prior to CDG Therapeutics, he was Director of Accounting for Northfield Laboratories, Inc. from 1998 to 2005.
Mr. Fleck received a BA degree in Economics from the University of Illinois in 1984 and an MBA from Northern Illinois University in 1987.
Postes actifs de Steven E. Fleck
| Sociétés | Poste | Début |
|---|---|---|
CDG Therapeutics, Inc.
 CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL. | Directeur Financier/CFO | 01/04/2006 |
Anciens postes connus de Steven E. Fleck
| Sociétés | Poste | Fin |
|---|---|---|
Northfield Laboratories, Inc.
 Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Comptroller/Controller/Auditor | 01/01/2005 |
Formation de Steven E. Fleck
| University of Illinois | Undergraduate Degree |
| Northern Illinois University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
CDG Therapeutics, Inc.
CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL. | Health Technology |
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Health Technology |
